Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
FDC ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
FDC Mar-23 |
ACTAVIS Dec-18 |
FDC/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 318 | 16,126 | - | |
Low | Rs | 229 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 107.5 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | 11.7 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | 14.0 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 119.5 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 165.91 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.5 | 3.4 | 74.7% | |
Avg P/E ratio | x | 23.4 | -10.6 | -221.4% | |
P/CF ratio (eoy) | x | 19.5 | 32.3 | 60.3% | |
Price / Book Value ratio | x | 2.3 | 0.8 | 277.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 45,368 | 4,480,758 | 1.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 3,909 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 17,838 | 1,315,689 | 1.4% | |
Other income | Rs m | 512 | 25,160 | 2.0% | |
Total revenues | Rs m | 18,350 | 1,340,849 | 1.4% | |
Gross profit | Rs m | 2,496 | 34,478 | 7.2% | |
Depreciation | Rs m | 389 | 562,428 | 0.1% | |
Interest | Rs m | 41 | 75,923 | 0.1% | |
Profit before tax | Rs m | 2,578 | -578,713 | -0.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | 640 | -7,334 | -8.7% | |
Profit after tax | Rs m | 1,938 | -423,784 | -0.5% | |
Gross profit margin | % | 14.0 | 2.6 | 534.0% | |
Effective tax rate | % | 24.8 | 1.3 | 1,958.2% | |
Net profit margin | % | 10.9 | -32.2 | -33.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,431 | 539,627 | 2.7% | |
Current liabilities | Rs m | 7,296 | 477,372 | 1.5% | |
Net working cap to sales | % | 40.0 | 4.7 | 845.4% | |
Current ratio | x | 2.0 | 1.1 | 175.0% | |
Inventory Days | Days | 265 | 20 | 1,352.8% | |
Debtors Days | Days | 251 | 66 | 378.5% | |
Net fixed assets | Rs m | 17,347 | 148,929 | 11.6% | |
Share capital | Rs m | 166 | 0 | - | |
Net worth | Rs m | 19,820 | 5,426,601 | 0.4% | |
Long term debt | Rs m | 6 | 1,910,903 | 0.0% | |
Total assets | Rs m | 31,796 | 8,483,012 | 0.4% | |
Interest coverage | x | 64.1 | -6.6 | -967.6% | |
Debt to equity ratio | x | 0 | 0.4 | 0.1% | |
Sales to assets ratio | x | 0.6 | 0.2 | 361.7% | |
Return on assets | % | 6.2 | -4.1 | -151.8% | |
Return on equity | % | 9.8 | -7.8 | -125.2% | |
Return on capital | % | 13.2 | -4.8 | -272.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,549 | 470,046 | 0.3% | |
From Investments | Rs m | 111 | 258,229 | 0.0% | |
From Financial Activity | Rs m | -1,800 | -806,740 | 0.2% | |
Net Cashflow | Rs m | -138 | -78,073 | 0.2% |
Compare FDC With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare FDC With: SAKAR HEALTHCARE MEDICAMEN BI GSK PHARMA PARNAX LAB SURYA PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.